MYGN - Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device | Benzinga
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office has granted a patent that covers the use of push-button blood collection devices for PCR-based fetal sex determination.
U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad's SneakPeek Snap® products in the U.S through 2040. The patent further covers technology for improving the accuracy of a fetal sex test by reducing contaminating DNA in maternal blood samples. SneakPeek's blood collection innovation makes obtaining a blood sample at home quick and easy. Consumers place the Snap device on their arm, press the button, and the sample is collected in one to four minutes. Moreover, clinical studies have shown that the Snap device significantly reduces the risk of external male DNA ...